IDEXX Laboratories Reports Strong Q3 2026 Results and Raises Full-Year Guidance

Executive Summary

On November 2, 2026, IDEXX Laboratories, Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) disclosing financial results for the third quarter ended September 30, 2026, and providing an updated full-year 2026 outlook.

Third Quarter 2026 Financial Highlights

• Revenue: Reported revenues of $1,214 million, representing a 10% increase year-over-year on both a reported and organic basis. Growth was anchored by the Companion Animal Group (CAG), which grew 10% reported and organic.
• CAG Diagnostics Recurring Revenue: Increased 11% reported and organic, including 13% reported (14% organic) in international markets and 10% in the U.S.
• Earnings Per Share (EPS): Diluted EPS reached $4.01, up 18% as reported and 22% on a comparable basis. The figure includes a $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share tax benefit from share-based compensation, and $0.04 per share benefit from currency fluctuations.
• Margins:
  • Gross Margin: 62.9%, an expansion of 110 basis points reported and 90 basis points on a comparable basis.
  • Operating Margin: 33.1%, up 100 basis points reported and 60 basis points comparable, despite a 10% increase in operating expenses associated with commercial investments and CoVet acquisition costs.
• Instrument Placements: Installed over 1,900 IDEXX inVue Dx™ analyzers during the quarter, bringing the total installed base to nearly 11,000 units.

Updated Full-Year 2026 Outlook

IDEXX raised its revenue and EPS projections for fiscal year 2026:

• Revenue: Increased to $4,741 million – $4,767 million (midpoint raised by $32 million), reflecting reported growth of 10.1% – 10.8% and organic growth of 9.3% – 10.0%.
• CAG Diagnostics Recurring Revenue Growth: Projected at 11.0% – 11.7% reported (10.3% – 11.0% organic).
• Operating Margin: Adjusted slightly to 32.1% – 32.3% (from 32.3% – 32.5%), reflecting acquisition-related impacts while maintaining 50 – 70 bps of year-over-year expansion.
• Diluted EPS: Raised to $14.96 – $15.16 (an increase of $0.25 at the midpoint relative to prior guidance).
• Capital Expenditures & Cash Flow: Free cash flow conversion projected at 95% – 100% of net income, with capital expenditures guided to approximately $160 million.

Strategic Developments

• CoVet Acquisition: The company integrated CoVet, an AI clinical assistant focused on enhancing veterinary team productivity and diagnostic utilization.
• Upcoming Catalyst: Announcement of an Investor and Analyst Session at VMX in Orlando on January 18, 2027, featuring IDEXX's next-generation point-of-care analyzer, IDEXX MultiCue Dx™.